FL S0632

Chronically and terminally ill patients have the right, with guidance from their health care providers, to determine individual courses of treatment using individualized or specialized prescription drugs obtained from compounding pharmacies

Compounding pharmacies licensed under chapter 465 (classified as 503A by the FDA) may obtain active pharmaceutical ingredients (APIs) that lack a United States Pharmacopeia, National Formulary, or Food Chemicals Codex monograph for use in compounding treatments for these patients

APIs must be purchased from an FDA-registered manufacturer, repackager, relabeler, or wholesaler and must arrive in Florida with a certificate of analysis detailing quality specifications

The authorization does not apply to any API that has been withdrawn or removed from the market by the FDA for safety and efficacy reasons, or placed on the FDA's Interim 503A Category 2 or 3 Bulk Drug Substances List, unless the substance meets the section's requirements

The bill explicitly prohibits any treatment or use of medication intended to cause the death of a patient, with an effective date of July 1, 2025